Third-generation CAR T-cell therapy shows promising efficacy and safety in heavily pretreated CLL patients, with a 67% complete response rate. The new CAR T-cell generation aims to mitigate ...

Breyanzi was granted accelerated approval in early 2024 to treat CLL/SLL based on data from a separate cohort of TRANSCEND CLL 004, in which 20% of patients achieved a complete response (CR). Breyanzi ...

IC9 CAR.19 is under clinical development by Bellicum Pharmaceuticals and currently in Phase I for Chronic Lymphocytic Leukemia (CLL). According to GlobalData, Phase I drugs for Chronic Lymphocytic ...

Breyanzi is the first CAR T cell therapy approved for CLL, and it is recommended for patients who have progressed on Bruton’s tyrosine kinase (BTK) and BCL2 inhibitors. Patients who fail both ...

Among patients who maintained a response to CAR T-cell therapy for at least 1 year, the median progression-free survival and overall survival were not reached at a median follow-up of 6.5 years.

At the time of follow-up for this study, the median PFS was 24.6 months among patients with a complete or partial response. Patients with Richer transformation (RT) may benefit from CD19-targeting ...

CAR-T Therapy: A Cure for CLL? Long-term follow-up data from patients enrolled in 2 trials suggested that anti-CD19 CAR T-cell therapy, with or without ibrutinib, can produce durable responses and ...

Chronic lymphocytic leukemia (CLL) often causes overwhelming fatigue that does not go away with rest. A person may be able to manage fatigue due to CLL with lifestyle changes and dietary adjustments.

The top 5 most-read articles about chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) on AJMC.com this year included findings on potential sequelae of these hematological ...